6 completed, 1 recruiting, 1 terminated. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 6, Recruiting 1, Terminated 1 |
Follow CT-P6: new trials by email Literature Review of CT-P6 trials Research Report on CT-P6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Atezolizumab, Biopsy, Bone Scan - Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 190 | 2019-04-05 | 2026-05-29 |
| Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure - HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 315 | 2014-02-18 | 2026-10-06 |
| Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 203 | 2011-02-14 | 2026-06-02 |
| Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Cyclophosphamide, Docetaxel, Doxorubicin - HER2/Neu Positive, Progesterone Receptor Positive | Phase 3 | Completed | National Cancer Institute (NCI) | 3270 | 2011-02-08 | 2025-07-14 |
| Demonstrate Efficacy and Safety of Metastatic Breast Cancer CT-P6, Herceptin, Paclitaxel - Metastatic Breast Cancer | Phase 3 | Completed | Celltrion | 475 | 2010-06-01 | 2025-02-11 |
| Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery Laboratory Biomarker Analysis, Lapatinib Ditosylate, Paclitaxel - Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7 | Phase 3 | Completed | National Cancer Institute (NCI) | 305 | 2009-02-24 | 2026-08-12 |
| Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation - Breast Ductal Carcinoma In Situ | Phase 3 | Completed | National Cancer Institute (NCI) | 2014 | 2008-12-10 | 2025-06-12 |
Breast Neoplasms (5) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms, Male (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Esophageal Neoplasms (1)
National Cancer Institute (NCI) (6) · Celltrion (1) · SWOG Cancer Research Network (1)
United States (7) · Puerto Rico (4) · Canada (3) · South Korea (2) · Ireland (1)
Charles E Geyer (1) · Howard P Safran (1) · Investigational Site (1) · Lisa A Carey (1) · Louis Fehrenbacher (1) · Mariya Rozenblit (1) · Melody A Cobleigh (1) · Mothaffar F Rimawi (1)
PMID 23984897, PMID 26527775, PMID 31821109, PMID 33095682, PMID 33739848, PMID 35038433, PMID 40170372, PMID 40480221
U10CA180868 (5), U10CA012027 (3), U10CA021661 (1), U10CA031946 (1), U10CA180821 (1), U10CA180830 (1), U10CA180888 (1)